Focal's sealant to get expedited FDA review:
This article was originally published in Clinica
Executive Summary
The premarket approval application for US firm Focal's FocalSeal-L surgical sealant has been accepted by the FDA under its expedited review procedures. FocalSeal is a synthetic absorbable liquid for sealing air leaks from the lungs during thoracic surgery. The sealant is sold in Europe under licence by Johnson & Johnson subsidiary Ethicon as AdvaSeal.